Neutralising antibody responses in cattle and sheep following booster vaccination with two commercial inactivated bluetongue virus serotype 8 vaccines

Veterinary Journal

Volumn 188, Issue 2, 2011, Pages 193-196

  Bartram, David J ^a   Heasman, Lindsay ^b   Batten, Carrie A ^c   Oura, Christopher A L ^c   Plana Durán, Joan ^d   Yuen, Ho Ming ^e   Wylie, Andrew D M ^a  

^a ZOETIS   (United States)

^b WESTPOINT VETERINARY GROUP   (United Kingdom)

^c INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^d Fort Dodge Veterinaria SA   (Spain)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Bluetongue; Booster; Inactivated vaccine; Neutralising antibodies

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLUETONGUE; BLUETONGUE ORBIVIRUS; CATTLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; IMMUNOGENICITY; MALE; REVACCINATION; SEROTYPE; SHEEP; VIRUS INACTIVATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BLUETONGUE; BLUETONGUE VIRUS; CATTLE; FEMALE; IMMUNIZATION, SECONDARY; MALE; SHEEP; VACCINES, INACTIVATED; VIRAL VACCINES;

BLUETONGUE VIRUS 8; BOS; OVIS ARIES;

EID: 79953783646     PISSN: 10900233     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tvjl.2010.04.001     Document Type: Article

References (26)

1. Animal Health, 2008. Vaccines. In: Official Veterinarian Issue 2. November 2008. Worcester, Animal Health, p. 4. <> (accessed 21.10.09). http://www.defra.gov.uk/animalhealth/publications/OV/OVnewsletter%202.pdf.
2. Bröker M., Schöndorf I. Are tick-borne encephalitis vaccines interchangeable?. Expert Review of Vaccines 2006, 5:461-466.
3. Clarke P., Kitchin N., Souverbie F. A randomised comparison of two inactivated hepatitis A vaccines, Avaxim and Vaqta, given as a booster to subjects primed with Avaxim. Vaccine 2001, 19:4429-4433.
4. Eschbaumer M., Hoffmann B., König P., Teifke J.P., Gethmann J.M., Conraths F.J., Probst C., Mettenleiter T.C., Beer M. Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep. Vaccine 2009, 27:4169-4175.
5. European Commission, 2008. Commission Decision of 24 July 2008 approving the emergency vaccination plans against bluetongue of certain Member States and fixing the level of the Community's financial contribution for 2007 and 2008. Official Journal of the European Union L214/66 (09 August 2008). <> (accessed 21.10.09). http://ec.europa.eu/food/animal/diseases/controlmeasures/docs/decision_2008-288-bt-vaccination.pdf.
6. Gethmann J., Hüttner K., Heyne H., Probst C., Ziller M., Beer M., Hoffmann B., Mettenleiter T.C., Conraths F.J. Comparative safety study of three inactivated BTV-8 vaccines in sheep and cattle under field conditions. Vaccine 2009, 27:4118-4126.
7. Gloster J., Burgin L., Witham C., Athanassiadou M., Mellor P.S. Bluetongue in the United Kingdom and northern Europe in 2007 and key issues for 2008. Veterinary Record 2008, 162:298-302.
8. Haig D.A., McKercher D.G., Alexander R.A. The cytopathic action of bluetongue virus in tissue culture and its application to the detection of antibodies in the serum of sheep. Onderstepoort Journal of Veterinary Research 1956, 27:171-177.
9. Heldens J.G.M., Weststrate M.W., van den Hoven R. Area under the curve as a tool to compare the efficacy of equine influenza vaccines - a retrospective analysis of three independent field trials. Journal of Immunological Methods 2002, 264:11-17.
10. Hofmann M.A., Renzullo S., Mader M., Chaignat V., Worwa G., Thuer B. Genetic characterization of Toggenburg orbivirus, a new bluetongue virus, from goats, Switzerland. Emerging Infectious Diseases 2008, 14:1855-1861.
11. Jeggo M.H., Wardley R.C., Taylor W.P. Role of neutralising antibody in passive immunity to bluetongue infection. Research in Veterinary Science 1984, 36:81-86.
12. Jeggo M.H., Wardley R.C., Brownlie J. Importance of ovine cytotoxic T cells in protection against bluetongue virus infection. Progress in Clinical and Biological Research 1985, 178:477-487.
13. Matthews J.N.S., Altman D.G., Campbell M.J., Royston P. Analysis of serial measurements in medical research. British Medical Journal 1990, 300:230-235.
14. Oura C.A.L., Wood J.L.N., Sanders A.J., Bin-Tarif A., Henstock M., Edwards L., Floyd T., Simmons H., Batten C.A. Seroconversion, neutralising antibodies and protection in bluetongue serotype 8 vaccinated sheep. Vaccine 2009, 27:7326-7330.
15. Pozzo F.D., Saegerman C., Thiry E. Bovine infection with bluetongue virus with special emphasis on European serotype 8. The Veterinary Journal 2009, 182:142-151.
16. Roy P., Boyce M., Noad R. Prospects for improved bluetongue vaccines. Nature Reviews Microbiology 2009, 7:120-128.
17. Savini G., MacLachlan N.J., Sanchez-Vizcaino J.-M., Zientara S. Vaccines against bluetongue in Europe. Comparative Immunology, Microbiology and Infectious Diseases 2008, 31:101-120.
18. Schwartz-Cornil I., Mertens P.P.C., Contreras V., Hemati B., Pascale F., Bréard E., Mellor P.S., MacLachlan N.J., Zientara S. Bluetongue virus: virology, pathogenesis and immunity. Veterinary Research 2008, 39:46. 10.1051/vetres:2008023.
19. Shaw A.E., Monaghan P., Alpar H.O., Anthony S., Darper K.E., Batten C.E., Guercio A., Alimena G., Vitale M., Bankowska K., Carpenter S., Jones H., Oura C.A.L., King D.P., Elliott H., Mellor P.S., Mertens P.P.C. Development and initial evaluation of a real-time RT-PCR assay to detect bluetongue virus genome segment 1. Journal of Virological Methods 2007, 145:115-126.
20. Stott J.L., Osburn B.I., Barber T.L., Sawyer M.M. Immunological response of sheep to an inactivated BTV vaccine. Journal of the American Veterinary Medical Association 1979, 175:611-615.
21. Veterinary Medicines Directorate, 2008a. Bovilis BTV8, UK Public Assessment Report Module 2. Scientific Discussion. <> (accessed 21.10.09). http://www.vmd.gov.uk/productinformationdatabase/Documents/209419.doc.
22. Veterinary Medicines Directorate, 2008b. Zulvac 8 Bovis, UK Public Assessment Report Module 2. Scientific Discussion. <> (accessed 21.10.09). http://www.vmd.gov.uk/productinformationdatabase/Documents/221556.doc.
23. Veterinary Medicines Directorate, 2008c. Zulvac 8 Ovis, UK Public Assessment Report Module 2. Scientific Discussion. <> (accessed 21.10.09). http://www.vmd.gov.uk/productinformationdatabase/Documents/251447.doc.
24. VICH, 2000. International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Products, GL9 (GCP). <> (accessed 21.10.09). http://www.vichsec.org/pdf/2000/Gl09_st7.pdf.
25. Wittermann C., Schöndorf I., Gniel D. Antibody response following administration of two paediatric tick-borne encephalitis vaccines using two different vaccination schedules. Vaccine 2009, 27:1661-1666.
26. Zuckerman J.N., Kirkpatrick C.T., Huang M. Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL.U) as a booster following primary immunization with Havrix (1440 EL.U) against hepatitis A. Journal of Travel Medicine 1998, 5:18-22.